Firma Kuros Biosciences, Autor bei Presse-Blog

Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting

28. September 2021 Firma Kuros BiosciencesMedizintechnikbone, bony, cells, cervical, easypack, extender, graft, kuros, magnetos, osseous, patients, posterolateral, putty, statements, with

. New products expand perioperative solutions for surgeons Data to be presented on new formulation of MagnetOs that includes a collagen carrier Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it Mehr

Kuros Biosciences Reports Results for First Half 2021

11. August 202111. August 2021 Firma Kuros BiosciencesFinanzen / Bilanzenbone, checkmate, chf, ecm, fibrin, Gold, implant, kuros, magnetos, patients, posterolateral, pth, statements, with, wound

. Financial Highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021 Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals Acceleration of product sales to CHF 3.6 million, up from CHF 1.3 Mehr

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

15. Juli 202115. Juli 2021 Firma Kuros BiosciencesForschung und Entwicklung??royalties??, ??royalty??, bone, checkmate, fibrin, graft, kuros, magnetos, pth, revenue, statements, tlr9, vidutolimod, with, xoma

Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the Mehr

Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration

22. Juni 202122. Juni 2021 Firma Kuros BiosciencesForschung und Entwicklungbone, cells, cervical, clinical, ecm, graft, kuros, magnetos, patients, power, spinal, statements, sur, with, wound

. First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed Mehr

Kuros Biosciences to present at upcoming U.S. spine conferences

17. Juni 2021 Firma Kuros BiosciencesForschung und Entwicklungbone, cns, equiva, fibrin, Gold, implant, kuros, magnetos, mountain, osseous, posterolateral, pth, statements, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical Mehr

Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations

2. Juni 20219. Juni 2022 Firma Kuros BiosciencesGesundheit & Medizinany, biosciences, cells, clinical, covid, economic, FDA, financial, kuros, magnetos, statements, testament, travel, with, wound

MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020 European distribution network expansion ahead of schedule Key commercial events in Australia, UK Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today pro-vided an update Mehr

Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals

17. Mai 2021 Firma Kuros BiosciencesAllgemein??royalties??, bone, checkmate, dosing, financial, fu?r, graft, immunotherapies, kuros, patients, payment, statements, treatment, unresectable, with

. • Milestone triggered by Checkmate’s initiation of potential registration trial of vidutolimod (CMP-001) in patients with anti-PD-1 refractory advanced melanoma • Kuros stands to receive up to $49 million additional milestones plus royalties on sales Kuros Biosciences Mehr

Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion

5. Mai 2021 Firma Kuros BiosciencesFirmeninternbiosciences, bone, clinical, derivatives, fibrin, financial, graft, kuros, market, orthobiologics, patients, pth, spinal, statements, with

Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical Formulation for Use in Spinal Fusion’. This patent claims certain Mehr

Kuros Biosciences publishes invitation to the Annual General Meeting 2021

29. März 2021 Firma Kuros BiosciencesFirmeninternbone, cells, chf, clinical, dividend, fibrin, graft, kuros, magnetos, orthobiologics, pth, spinal, statements, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today published the invitation and agenda for its Annual General Meeting, to be held on April 19, 2021, 11.00 Mehr

Kuros Biosciences reports results for the full year 2020

18. März 2021 Firma Kuros BiosciencesFinanzen / Bilanzenbone, checkmate, chf, fibrin, Gold, graft, kuros, magnetos, orthobiologics, patients, pth, revenues, statements, tlif, with

Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020 Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated Phase II clinical study of Fibrin-PTH in spine Commercial rollout in the Mehr

Autor: Firma Kuros Biosciences